[The modulation of hemostatic reactions in vitro and in vivo by representatives of regulatory peptide families].
Data available in the literature and the author's own findings of the effects of regulatory peptide (RP) and their analogues are summarized. MIF, TRH, and its analog PR-546, the paraopioid RP, leuenkephalin, dalargin, the ACTH analogue Semax, tafcin, thymosine, interleukin-1, vasopressin, oxytocin, bradykinin, defencin, and some proline-containing oligopeptides, such as Pro-Gly, Gly-Pro, Trp-Pro, Pro-Gly-Pro, Gly-Pro-Gly-Gly were studied. A complex of in vitro and in vivo tests identified three groups of RP: 1) neutral ones as to the hemostatic reactions studied; 2) stimulants of hypercoagulation and fibrin polymerization; 3) inhibitors of blood coagulation, increased fibrinolysis, and fibrin demopolymerization. The fibrinolytic and antithrombotic effects of Semax (in vivo), the procoagulative action of defencin, and the enhanced anticoagulant effects in the combinations of Semax-heparin and tafcin (in vivo) attract particular attention. Semax alone and in combination with heparin is recommended for clinical studies in respective hemostatic abnormalities.
Ashmarin
I P
IP
Liapina
L A
LA
Pastorova
V E
VE
D000281:Administration, Intranasal; D000818:Animals; D001778:Blood Coagulation Disorders / Q000097:blood; D004305:Dose-Response Relationship, Drug; D006487:Hemostasis / Q000187:drug effects*; D006493:Heparin / Q000494:pharmacology; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D009479:Neuropeptides / Q000008:administration & dosage / Q000494:pharmacology*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000494:pharmacology; D051381:Rats; D013997:Time Factors
D009479:Neuropeptides; D010446:Peptide Fragments; D006493:Heparin